Diabetes Mellitus Type 2 Perspective

 
 
  • SGLT2 Inhibitors vs GLP-1 Agonists: Go It Alone or Join Forces?   Should SGLT2 Inhibitors and GLP-1 agonists be prescribed singly or jointly? Drs Matthew Budoff and Yehuda Handelsman discuss the options.
  • Episode 5: Type 2 Diabetes Care Equity: What Can You Do?   Are health equity and better outcomes within reach for all patients with type 2 diabetes? Drs Enrique Caballero and Silvio Inzucchi discuss how we can change the status quo.
  • HFrEF: Advances in Management   Drs Javed Butler, Biykem Bozkurt, and Alanna Morris discuss how novel agents have been incorporated into current therapeutic regimens.
  • Managing Chronic Kidney Disease in Patients With Diabetes   Dr Sylvia Rosas discusses managing chronic kidney disease in patients with diabetes, as outlined in updated ADA 2022 Standards of Medical Care in Diabetes.
  • ENDO 2022 Read clinically focused news coverage of key developments from ENDO 2022
  • Recording Weight Advisable at All Ages in General Medicine In general practice, recording a patient's weight helps detect those at risk of metabolic syndrome, but this task is not performed routinely for men or patients with no comorbidities.
  • ADA 2022 Read clinically focused news coverage of key developments from ADA 2022
  • 'Turning Red' Provides Positive Depiction of Diabetes Pixar's newest animated film features two background characters with visible diabetes technology, a leap forward in portrayals of diabetes in mainstream media.
  • Type 2 Diabetes With Obesity   Experts in endocrinology, psychology, and diet collaborate on a management plan for a patient with type 2 diabetes who has been struggling with glycemic control, weight loss, and mild depression.
  • Beyond Glucose: Reducing CVD in Patients With Diabetes: Modifying all Factors   UC cardiologists discuss the need for a combination of lifestyle modification and risk-reduction therapy to optimally manage CVD risk in patients with diabetes.
  • Tirzepatide: 'Exciting' and Promising in Lowering A1c   Tirzepatide is the newest player in the quest for lowering A1c in people with type 2 diabetes. Dr Anne Peters describes the novel agent -- what it can do for patients now and in the future.
  • Episode 4: Better Ways to Sustain Weight Loss in Type 2 Diabetes   Patients with type 2 diabetes and obesity have more options today than ever before. Join host Dr Silvio Inzucchi and obesity expert Dr Ania Jastreboff as they discuss ways to support weight loss.
  • Does COVID-19 Raise the Risk for Diabetes?   Is COVID-19 responsible for new-onset diabetes? Or are COVID infections bringing to light previously undiagnosed cases? Dr Anne Peters reviews recent studies around COVID and diabetes.
  • AACE 2022 Read clinically focused news coverage of key developments from AACE 2022
  • Diabetes & Kidney Disease: A Heart in Jeopardy: Helping a Hero   An Air Force veteran with CKD shares his experience managing multiple chronic conditions and participating in research trials.
  • Therapies 'Not Used Enough' in Patients With T2D and CVD Risk   Dr Anne Peters discusses a paper demonstrating the low use of appropriate therapies in patients with type 2 diabetes and established cardiovascular risk.
  • Key Points From the New Heart Failure Guidelines   Dr Ileana Piña discusses the 2022 AHA/ACC/HFSA heart failure guidelines and how they compare with the European guidelines and recent data on heart failure.
  • Beyond Glucose: Reducing CVD in Patients With Diabetes: Integrative Approach   Cardiologists discuss the multiple evidence-based treatment modalities, such as acupuncture, included in the UC Irvine preventive cardiology program.
  • Diabetes and Heart Disease Highlights From ACC 2022   Dr Martha Gulati shares key reports from ACC 2022, including updates on SGLT2 inhibitors from the SCORED trial, chronic hypertension in pregnancy, and heart-healthy diet education in supermarkets.
  • Top Abstracts in Atherosclerosis and Lipid Management From ACC 2022   Key data on atherosclerosis and lipids from ACC 2022 include PACMAN-AMI results with alirocumab, a new look at waist circumference in REDUCE-IT, and a subgroup analysis of SCORED with sotagliflozin.